ID
12964
Description
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00193063
Link
https://clinicaltrials.gov/show/NCT00193063
Keywords
Versions (1)
- 1/7/16 1/7/16 -
Uploaded on
January 7, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Breast Cancer NCT00193063
Eligibility Breast Cancer NCT00193063
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
gemcitabine
Data type
boolean
Alias
- UMLS CUI [1]
- C0045093
Description
brain metastases
Data type
boolean
Alias
- UMLS CUI [1]
- C0220650
Description
comorbidity
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0009488
- UMLS CUI [1,2]
- C0205082
Description
additional inclusion/exclusion criteria
Data type
boolean
Similar models
Eligibility Breast Cancer NCT00193063
- StudyEvent: Eligibility
C0027627 (UMLS CUI [1,2])
C0242957 (UMLS CUI [2])
C0005953 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0205082 (UMLS CUI [1,2])